Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GB 3007

Next Previous
Drug Profile

GB 3007

Alternative Names: GB-3007; GB3007 NY-ESO1 TCR-T; GB3007 NY-ESO1 TCRT injection

Latest Information Update: 28 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Genbase Biotechnology
  • Developer Shanghai Genbase Biotechnology; Shanghai Genechem
  • Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Synovial sarcoma
  • No development reported Multiple myeloma

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for preclinical development in Multiple-myeloma in China (Parenteral, Injection)
  • 01 Apr 2022 Preclinical trials in Synovial sarcoma in China (Parenteral) before April 2022 (Shanghai Genechem pipeline, April 2022)
  • 01 Oct 2020 Shanghai Genbase Biotechnology plans a phase I trials in Multiple myeloma (Second-line therapy or greater) in China (Parenteral) (ChiCTR2000035553 )

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top